RESUMO
BACKGROUND: The incidental use of statins during radiation therapy has been associated with a reduced long-term risk of developing atherosclerotic cardiovascular disease. We examined whether irradiation causes chronic vascular injury and whether short-term administration of statins during and after irradiation is sufficient to prevent chronic injury compared with long-term administration. METHODS AND RESULTS: C57Bl/6 mice were pretreated with pravastatin for 72 hours and then exposed to 12 Gy X-ray head-and-neck irradiation. Pravastatin was then administered either for an additional 24 hours or for 1 year. Carotid arteries were tested for vascular reactivity, altered gene expression, and collagen deposition 1 year after irradiation. Treatment with pravastatin for 24 hours after irradiation reduced the loss of endothelium-dependent vasorelaxation and protected against enhanced vasoconstriction. Expression of markers associated with inflammation (NFκB p65 [phospho-nuclear factor kappa B p65] and TNF-α [tumor necrosis factor alpha]) and with oxidative stress (NADPH oxidases 2 and 4) were lowered and subunits of the voltage and Ca2+ activated K+ BK channel (potassium calcium-activated channel subfamily M alpha 1 and potassium calcium-activated channel subfamily M regulatory beta subunit 1) in the carotid artery were modulated. Treatment with pravastatin for 1 year after irradiation completely reversed irradiation-induced changes. CONCLUSIONS: Short-term administration of pravastatin is sufficient to reduce chronic vascular injury at 1 year after irradiation. Long-term administration eliminates the effects of irradiation. These findings suggest that a prospective treatment strategy involving statins could be effective in patients undergoing radiation therapy. The optimal duration of treatment in humans has yet to be determined.
Assuntos
Inibidores de Hidroximetilglutaril-CoA Redutases , Camundongos Endogâmicos C57BL , Estresse Oxidativo , Pravastatina , Animais , Pravastatina/farmacologia , Inibidores de Hidroximetilglutaril-CoA Redutases/farmacologia , Estresse Oxidativo/efeitos dos fármacos , Estresse Oxidativo/efeitos da radiação , Fatores de Tempo , Vasoconstrição/efeitos dos fármacos , Vasoconstrição/efeitos da radiação , Vasodilatação/efeitos dos fármacos , Vasodilatação/efeitos da radiação , Masculino , NADPH Oxidase 2/metabolismo , NADPH Oxidase 2/genética , Fator de Necrose Tumoral alfa/metabolismo , Fator de Transcrição RelA/metabolismo , NADPH Oxidases/metabolismo , Camundongos , Lesões Experimentais por Radiação/prevenção & controle , Lesões Experimentais por Radiação/metabolismo , Lesões Experimentais por Radiação/tratamento farmacológico , Esquema de Medicação , Artérias Carótidas/efeitos da radiação , Artérias Carótidas/efeitos dos fármacos , Doença Crônica , Modelos Animais de Doenças , NADPH Oxidase 4RESUMO
BACKGROUND: This study aimed to evaluate the effects of rosuvastatin and pravastatin on glucose homeostasis and other biomarkers in individuals at high risk of developing diabetes. METHODS: This prospective, randomized, open-labeled, and controlled trial included prediabetic individuals with impaired fasting glucose and impaired glucose tolerance. The participants were randomized into three groups: rosuvastatin (10 mg), pravastatin (40 mg), or control. Biomarkers of diabetes and glucose and insulin responses to oral glucose tolerance tests were assessed at baseline and after 6 months of treatment. The primary outcomes were comparisons of glucose homeostasis and biomarkers of diabetes among groups at baseline and after 6 months of treatment. RESULTS: A total of 141 subjects with impaired fasting glucose (IFG) were screened and 41 participants were recruited. Twenty-two subjects were randomized to either the rosuvastatin or pravastatin group and 19 subjects were assigned to the control group. After 6 months of treatment, all groups had similar cholesterol and triglyceride levels. Likewise, HbA1c levels, glucose, and insulin excursions during oral glucose tolerance test, were similar among the three groups. However, compared to the other groups, the rosuvastatin group had higher homeostasis model assessment for insulin resistance (HOMA-IR) (insulin resistance) and a lower Matsuda index (insulin sensitivity). CONCLUSION: Among prediabetic individuals with IFG, rosuvastatin treatment was associated with increased insulin resistance and decreased insulin sensitivity compared to pravastatin and control groups. Further research is needed to elucidate the underlying mechanisms and clinical implications of these findings.
Assuntos
Glicemia , Homeostase , Inibidores de Hidroximetilglutaril-CoA Redutases , Pravastatina , Estado Pré-Diabético , Rosuvastatina Cálcica , Humanos , Estado Pré-Diabético/tratamento farmacológico , Estado Pré-Diabético/sangue , Rosuvastatina Cálcica/uso terapêutico , Masculino , Inibidores de Hidroximetilglutaril-CoA Redutases/uso terapêutico , Feminino , Pessoa de Meia-Idade , Estudos Prospectivos , Homeostase/efeitos dos fármacos , Pravastatina/uso terapêutico , Pravastatina/farmacologia , Glicemia/análise , Glicemia/efeitos dos fármacos , Adulto , Resistência à Insulina , Teste de Tolerância a Glucose , IdosoRESUMO
Statin treatment may increase the risk of diabetes; there is insufficient data on how statins affect glucose regulation and glycemic control and the effects of statins on liver enzymes related to carbohydrate metabolism have not been fully studied. Therefore, we aimed to compare the effects of the statin derivatives, pravastatin, and rosuvastatin, on carbohydrate metabolism in an experimental diabetic rat model. Female Wistar albino rats were used and diabetes was induced by intraperitoneal injection of streptozotocin. Thereafter, 10 and 20 mg kg-1 day-1 doses of both pravastatin and rosuvastatin were administered by oral gavage to the diabetic rats for 8 weeks. At the end of the experiment, body masses, the levels of fasting blood glucose, serum insulin, insulin resistance (HOMA-IR), liver glycogen, and liver enzymes related to carbohydrate metabolism were measured. Both doses of pravastatin significantly in creased the body mass in diabetic rats, however, rosuvastatin, especially at the dose of 20 mg kg-1 day-1 reduced the body mass signi ficantly. Pravastatin, especially at a dose of 20 mg kg-1 day-1, caused significant increases in liver glycogen synthase and glucose 6-phosphate dehydrogenase levels but significant decreases in the levels of glycogen phosphorylase, lactate dehydrogenase, and glucose-6-phosphatase. Hence, pravastatin partially ameliorated the adverse changes in liver enzymes caused by diabetes and, especially at the dose of 20 mg kg-1 day-1, reduced the fasting blood glucose level and increased the liver glycogen content. However, rosuvastatin, especially at the dose of 20 mg kg-1 day-1, significantly reduced the liver glycogen synthase and pyruvate kinase levels, but increased the glycogen phosphorylase level in diabetic rats. Rosuvastatin, 20 mg kg-1 day-1 dose, caused significant decreases in the body mass and the liver glycogen content of diabetic rats. It can be concluded that pravastatin, especially at the dose of 20 mg kg-1 day-1 is more effective in ameliorating the negative effects of diabetes by modulating carbohydrate metabolism.
Assuntos
Diabetes Mellitus Experimental , Inibidores de Hidroximetilglutaril-CoA Redutases , Feminino , Ratos , Animais , Glicemia , Ratos Wistar , Rosuvastatina Cálcica/efeitos adversos , Pravastatina/farmacologia , Inibidores de Hidroximetilglutaril-CoA Redutases/farmacologia , Hipoglicemiantes/farmacologia , Diabetes Mellitus Experimental/induzido quimicamente , Diabetes Mellitus Experimental/tratamento farmacológico , Glicogênio Sintase/metabolismo , Glicogênio Sintase/farmacologia , Glicogênio Hepático/efeitos adversos , Glicogênio Hepático/metabolismo , Hemoglobinas Glicadas , Glucose/metabolismo , Metabolismo dos Carboidratos , Glicogênio Fosforilase/metabolismo , Glicogênio Fosforilase/farmacologia , Fígado/metabolismo , Insulina/farmacologiaRESUMO
Statins, widely prescribed for cholesterol management by inhibiting HMG-CoA reductase in the cholesterol biosynthesis pathway, may also influence vertebrate development. In this study, we investigated the developmental effects of two widely used statins, atorvastatin (ATO) and pravastatin (PRA), on zebrafish offspring. For ATO, we administered doses classified as low (1 µM), medium (5 µM), and high (10 µM), while for PRA, the corresponding concentrations were set at low (18 µM), medium (180 µM), and high (270 µM). Our results showed significant reductions in birth and hatching rates, along with decreased body length in offspring at all ATO concentrations and medium to high PRA concentrations. A notable increase in malformation rates, especially in the spine and heart, was observed across all ATO treatments and in medium and high PRA groups. Additionally, we observed reduced heart contraction rates, decreased heart size, lower bone volumes, and diminished expression of mRNA osteogenic markers. Elevated venous sinus-artery bulb (SV-BA) ratios, increased thoracic area, and abnormal cartilage development were also prominent in all ATO-treated groups. Transcriptome analysis revealed alterations in genes predominantly associated with ion channels. These findings provide insights into the potential impacts of specific concentrations of statins on offspring development and highlight potential gene interactions with statins.
Assuntos
Inibidores de Hidroximetilglutaril-CoA Redutases , Animais , Inibidores de Hidroximetilglutaril-CoA Redutases/toxicidade , Inibidores de Hidroximetilglutaril-CoA Redutases/uso terapêutico , Peixe-Zebra/genética , Transcriptoma , Pravastatina/farmacologia , Pravastatina/uso terapêutico , Atorvastatina/toxicidade , Canais IônicosRESUMO
BACKGROUND: Chemerin, an inflammatory adipokine, is upregulated in preeclampsia, and its placental overexpression results in preeclampsia-like symptoms in mice. Statins may lower chemerin. METHODS: Chemerin was determined in a prospective cohort study in women suspected of preeclampsia and evaluated as a predictor versus the sFlt-1 (soluble fms-like tyrosine kinase-1)/PlGF (placental growth factor) ratio. Chemerin release was studied in perfused placentas and placental explants with or without the statins pravastatin and fluvastatin. We also addressed statin placental passage and the effects of chemerin in chorionic plate arteries. RESULTS: Serum chemerin was elevated in women with preeclampsia, and its addition to a predictive model yielded significant effects on top of the sFlt-1/PlGF ratio to predict preeclampsia and its fetal complications. Perfused placentas and explants of preeclamptic women released more chemerin and sFlt-1 and less PlGF than those of healthy pregnant women. Statins reversed this. Both statins entered the fetal compartment, and the fetal/maternal concentration ratio of pravastatin was twice that of fluvastatin. Chemerin constricted plate arteries, and this was blocked by a chemerin receptor antagonist and pravastatin. Chemerin did not potentiate endothelin-1 in chorionic plate arteries. In explants, statins upregulated low-density lipoprotein receptor expression, which relies on the same transcription factor as chemerin, and NO release. CONCLUSIONS: Chemerin is a biomarker for preeclampsia, and statins both prevent its placental upregulation and effects, in an NO and low-density lipoprotein receptor-dependent manner. Combined with their capacity to improve the sFlt-1/PlGF ratio, this offers an attractive mechanism by which statins may prevent or treat preeclampsia.
Assuntos
Inibidores de Hidroximetilglutaril-CoA Redutases , Pré-Eclâmpsia , Humanos , Gravidez , Feminino , Animais , Camundongos , Placenta/metabolismo , Inibidores de Hidroximetilglutaril-CoA Redutases/farmacologia , Fator de Crescimento Placentário , Pravastatina/farmacologia , Regulação para Cima , Estudos Prospectivos , Pré-Eclâmpsia/tratamento farmacológico , Pré-Eclâmpsia/prevenção & controle , Fluvastatina/metabolismo , Fluvastatina/farmacologia , Receptor 1 de Fatores de Crescimento do Endotélio Vascular , Lipoproteínas LDL/metabolismo , Lipoproteínas LDL/farmacologia , Biomarcadores , Quimiocinas/metabolismo , Peptídeos e Proteínas de Sinalização Intercelular/metabolismoRESUMO
Early diagnosis and efficient treatment of preeclampsia remains a medical challenge and etiological factors converge in a deficient placentation that triggers oxidative stress. There is evidence that statins show antioxidant effects that can improve endothelial function without adverse perinatal effects. We aimed to compare early vs. late pravastatin treatment on the oxidative stress and cardiovascular features of an experimental model of preeclampsia. Female Wistar rats were randomly divided into preeclampsia phenotype rats (PEP) developed by sub renal aortic coarctation (SRAC) and healthy pregnant rats (C). Each group received pravastatin (5 mg/Kg) p.o. either for one week before and during the first week or during the last two weeks of gestation. Blood pressure was determined using the plethysmographic method. Phenylephrine (Phe)-induced contractility was evaluated in isolated thoracic and abdominal aortic rings with or without endothelium. Blood samples were obtained to determine anion superoxide concentration as indicator of NADPH activity. Two-way ANOVA and Bonferroni post hoc tests were used to define statistical significance. Early or late pravastatin treatment decreased hypertension of PEP animals but did not change BP of the healthy pregnant group. Thoracic and abdominal aorta from PEP rats showed increased contractility that was reverted by pravastatin early treatment in endothelium intact rings. Pravastatin did not significantly change contractility neither in the thoracic nor in the abdominal aorta segments from healthy pregnant control rats (C), and decrease anion superoxide concentration by NADPH activity. We conclude pravastatin can improve both blood pressure and endothelium-dependent Phe-induced contractility in an experimental model of preeclampsia by reducing oxidative stress.
Assuntos
Pravastatina , Pré-Eclâmpsia , Gravidez , Humanos , Ratos , Feminino , Animais , Pravastatina/farmacologia , Pravastatina/uso terapêutico , Pré-Eclâmpsia/tratamento farmacológico , Superóxidos/farmacologia , NADP/farmacologia , Ratos Wistar , Estresse Oxidativo , Fenilefrina/farmacologia , Endotélio VascularRESUMO
BACKGROUND: Early-stage breast cancer is usually treated with breast-conserving surgery followed by adjuvant radiation therapy. Acute skin toxicity is a common radiation-induced side effect experienced by many patients. Recently, a combination of bisphosphonates (zoledronic acid) and statins (pravastatin), or ZOPRA, was shown to radio-protect normal tissues by enhancing DNA double-strand breaks (DSB) repair mechanism. However, there are no studies assessing the effect of ZOPRA on cancerous cells. The purpose of this study is to characterize the in vitro effect of the zoledronic acid (ZO), pravastatin (PRA), and ZOPRA treatment on the molecular and cellular radiosensitivity of breast cancer cell lines. MATERIALS: Two breast cancer cell lines, MDA MB 231 and MCF-7, were tested. Cells were treated with different concentrations of pravastatin (PRA), zoledronate (ZO), as well as their ZOPRA combination, before irradiation. Anti-γH2AX and anti-pATM immunofluorescence were performed to study DNA DSB repair kinetics. MTT assay was performed to assess cell proliferation and viability, and flow cytometry was performed to analyze the effect of the drugs on the cell cycle distribution. The clonogenic assay was used to assess cell survival. RESULTS: ZO, PRA, and ZOPRA treatments were shown to increase the residual number of γH2AX foci for both cell lines. ZOPRA treatment was also shown to reduce the activity of the ATM kinase in MCF-7. ZOPRA induced a significant decrease in cell survival for both cell lines. CONCLUSIONS: Our findings show that pretreatment with ZOPRA can decrease the radioresistance of breast cancer cells at the molecular and cellular levels. The fact that ZOPRA was previously shown to radioprotect normal tissues, makes it a good candidate to become a therapeutic window-widening drug.
Assuntos
Neoplasias da Mama , Inibidores de Hidroximetilglutaril-CoA Redutases , Humanos , Feminino , Células MCF-7 , Reparo do DNA , Inibidores de Hidroximetilglutaril-CoA Redutases/farmacologia , Neoplasias da Mama/tratamento farmacológico , Neoplasias da Mama/radioterapia , Difosfonatos/farmacologia , Ácido Zoledrônico/farmacologia , Pravastatina/farmacologia , Tolerância a Radiação/efeitos da radiação , DNA , Linhagem Celular TumoralRESUMO
BACKGROUND: Pravastatin is an oral lipid-lowering drug, commonly used by patients with diabetes that is positively correlated with the occurrence of vascular calcification (VC), but the mechanism is unclear. METHODS: In this study, 16S rRNA sequencing and qRT-PCR wereused to detect the differential gut bacteria. Metabolomics and ELISA were used to analyze the differential metabolites. qRT-PCR and western blotting (WB) were used to detect genes expression. Flow cytometry was used to analyze macrophage phenotype. Immunohistochemistry was used to analyze aortic calcification. RESULTS: We found that gut Bacteroides fragilis (BF) increased significantly in patients who took pravastatin or type 2 diabetes (T2D) mice treated with pravastatin. In vitro experiments showed that pravastatin had little effect on BF but significantly promoted BF proliferation in vivo. Further analysis showed that ArsR was an important gene for pravastatin to regulate the activation of BF, and overexpression of ArsR significantly promoted the secretion of 3,4,5-trimethoxycinnamic acid (TMCA). Importantly, pravastatin significantly promoted BF secretion of TMCA and significantly increased TMCA secretion in T2D patients or T2D mice. TMCA had little effect on vascular smooth muscle cell calcification but significantly promoted macrophage M1 polarization, which we had demonstrated that M1 macrophages promoted T2D VC. In vivo studies found that pravastatin significantly upregulated TMCA levels in the feces and serum of T2D mice transplanted with BF and promoted the macrophage M1 polarization in bone marrow and the osteoblastic differentiation of aortic cells. Similar results were obtained in T2D mice after intravenous infusion of TMCA. CONCLUSIONS: Promoting intestinal BF to secrete TMCA, which leads to macrophage M1 polarization, is an important mechanism by which pravastatin promotes calcification, and the result will be used for the optimization of clinical medication strategies of pravastatin supplying a theoretical basis and experimental basis.
Assuntos
Bacteroides fragilis , Diabetes Mellitus Tipo 2 , Macrófagos , Pravastatina , Calcificação Vascular , Pravastatina/farmacologia , Animais , Calcificação Vascular/metabolismo , Calcificação Vascular/etiologia , Calcificação Vascular/patologia , Camundongos , Macrófagos/metabolismo , Macrófagos/efeitos dos fármacos , Humanos , Diabetes Mellitus Tipo 2/tratamento farmacológico , Diabetes Mellitus Tipo 2/metabolismo , Masculino , Microbioma Gastrointestinal/efeitos dos fármacos , Inibidores de Hidroximetilglutaril-CoA Redutases/farmacologia , Camundongos Endogâmicos C57BL , FemininoRESUMO
Abstract Multiple myeloma (MM) is a B cell bone marrow neoplasia characterized by inflammation with an intense secretion of growth factors that promote tumor growth, cell survival, migration and invasion. The aim of this study was to evaluate the effects of pravastatin, a drug used to reduce cholesterol, in a MM cell line.Cell cycle and viability were determinate by Trypan Blue and Propidium Iodide. IL6, VEGF, bFGF and TGFβ were quantified by ELISA and qRT-PCR including here de HMG CoA reductase. It was observed reduction of cell viability, increase of cells in G0/G1 phase of the cell cycle and reducing the factors VEGF and bFGF without influence on 3-Methyl-Glutaryl Coenzyme A reductase expression.The results demonstrated that pravastatin induces cell cycle arrest in G0/G1 and decreased production of growth factors in Multiple Myeloma cell line.
Resumo O Mieloma Múltiplo é uma neoplasia de linfócitos B da medula óssea, caracterizada por inflamação com uma intensa secreção de fatores de crescimento que promovem o aumento do volume do tumor, sobrevivência celular, migração e invasão. O objetivo deste estudo foi avaliar os efeitos da pravastatina, uma droga usada para reduzir o colesterol, em um linhagem de MM. O ciclo celular e viabilidade foram determinadas por Trypan Blue e iodeto de propídio. IL6, VEGF, bFGF e TGF foram quantificadas por ELISA e qRT-PCR, incluindo aqui de HMG CoA redutase. Observou-se a redução da viabilidade das células, aumento de células na fase G0/G1 do ciclo celular e redução no VEGF e bFGF, sem influência na expressão da enzima 3-Metil-Glutaril Coenzima A redutase. Os resultados demonstraram que a pravastatina induz parada no ciclo celular em G0/G1 e diminuição da produção de fatores de crescimento em várias linhas de células de Mieloma.
Assuntos
Humanos , Fatores de Crescimento de Fibroblastos/genética , Inibidores de Hidroximetilglutaril-CoA Redutases/farmacologia , Mieloma Múltiplo/metabolismo , Pravastatina/farmacologia , Fator A de Crescimento do Endotélio Vascular/genética , Anticolesterolemiantes/farmacologia , Linhagem Celular , Pontos de Checagem do Ciclo Celular/efeitos dos fármacos , Colesterol/metabolismo , Fatores de Crescimento de Fibroblastos/metabolismo , Fator A de Crescimento do Endotélio Vascular/metabolismoRESUMO
Results of numerous epidemiologic studies indicate that elevated serum cholesterol, especially the LDL fraction, is a major cause of coronary heart disease (CHD). Epidemiologic and angiographic evidence from primary and secondary prevention studies involving several HMG-CoA reducíase inhibitors (statins) indicate that decreasing elevated serum cholesterol concentration (specifically LDL-cholesterol) can reduce the incidence of CHD and/or progression of atherosclerosis and results in a decrease in associated morbidity and mortality. It has been estimated that each 1 percent reduction in LDL-cholesterol concentration may result in a 1 percent decrease in the incidence of CHD. Furthermore, an analysis of pooled data from primary and secondary prevention studies found that treatment with a statin for a median duration of 5.4 years was associated with a 31 percent and 21 percent reduction in the risk of major coronary events and total mortality, respectively. This paper deals with the pharmacology of statins, specially with the pleiotropic effects ofthese drugs.
Assuntos
Humanos , Anticolesterolemiantes/farmacologia , Antioxidantes/farmacologia , Aterosclerose/tratamento farmacológico , Inibidores de Hidroximetilglutaril-CoA Redutases/farmacologia , Endotélio Vascular/efeitos dos fármacos , Ácidos Graxos Monoinsaturados/farmacologia , Fluorbenzenos/farmacologia , Ácidos Heptanoicos/farmacologia , Hipercolesterolemia/tratamento farmacológico , Indóis/farmacologia , Lovastatina/farmacologia , Estresse Oxidativo/efeitos dos fármacos , Pravastatina/farmacologia , Pirimidinas/farmacologia , Pirróis/farmacologia , Sulfonamidas/farmacologiaRESUMO
OBJETIVO: Comparar os efeitos da atorvastatina, fluvastatina, pravastatina e simvastatina sobre a função endotelial, a aterosclerose aórtica e o teor de malonodialdeído (MDA) nas LDL nativas, oxidadas e na parede arterial de coelhos hipercolesterolêmicos, depois que as doses destas estatinas foram ajustadas para reduzir o colesterol total plasmático a valores similares. MÉTODOS: Coelhos machos, foram separados em grupos de 10 animais (n=10), chamados hipercolesterolêmico (controle), atorvastatina, fluvastatina, pravastatina e normal. A exceção do grupo normal, os animais foram alimentados com ração padrão acrescida de colesterol a 0,5 por cento e óleo de coco a 2 por cento durante 45 dias. As drogas foram administradas a partir do 15° dia do início do experimento e no 30° dia, as doses foram ajustadas, através do controle do colesterol plasmático, para obter valores semelhantes em cada grupo. Ao final do experimento foi dosado o colesterol plasmático e as lipoproteinas e retirado um segmento de aorta torácica para estudo da função endotelial, da peroxidação lipídica e exame histológico para medida da aterosclerose aórtica. RESULTADOS: As estatinas reduziram significantemente o colesterol total plasmático, as LDL-colesterol e a aterosclerose aórtica. O teor de MDA também foi significantemente reduzido nas LDL nativas e oxidadas, assim como na parede arterial. O relaxamento-dependente do endotélio foi significantemente maior no grupo tratado em comparação ao hipercolesterolêmico. CONCLUSÃO: As estatinas, em doses ajustadas, tiveram efeito significante e similar em reduzir a peroxidação lipídica nas LDL e na parede arterial, na regressão da aterosclerose aórtica e na reversão da disfunção endotelial.
Assuntos
Animais , Masculino , Coelhos , Anticolesterolemiantes/farmacologia , Doenças da Aorta/tratamento farmacológico , Arteriosclerose/tratamento farmacológico , Endotélio Vascular/efeitos dos fármacos , Hipercolesterolemia/tratamento farmacológico , Peroxidação de Lipídeos/efeitos dos fármacos , Doenças da Aorta/metabolismo , Doenças da Aorta/fisiopatologia , Arteriosclerose/metabolismo , Arteriosclerose/fisiopatologia , LDL-Colesterol/sangue , LDL-Colesterol/efeitos dos fármacos , Colesterol/sangue , Endotélio Vascular/metabolismo , Endotélio Vascular/fisiopatologia , Ácidos Graxos Monoinsaturados/farmacologia , Ácidos Heptanoicos/farmacologia , Hipercolesterolemia/metabolismo , Hipercolesterolemia/fisiopatologia , Indóis/farmacologia , Malondialdeído/análise , Pravastatina/farmacologia , Pirróis/farmacologia , Sinvastatina/farmacologiaRESUMO
Para evaluar la eficacia y la seguridad de 10mg/día de pravastatin en el tratamiento de la hipercolesterolemia primaria, 564 pacientes (con colesterolemia mayor de 240 mg/día al cabo de 4 semanas de dieta) fueron tratados durante 8 semanas. El perfil lipídico mejoró significativamente (p< 0,01) tanto a las 4 como a las 8 semanas de tratamiento. Sólo 42 pacientes (7,4 por ciento) presentaron efectos colaterales y no hubo cambios significativos en los parámetros no lipídicos. En conclusión, el pravastatin resultó ser una droga eficaz y segura para el tratamiento de la hipercolesterolemia primaria
Assuntos
Humanos , Masculino , Feminino , Adolescente , Adulto , Pessoa de Meia-Idade , Colesterol/metabolismo , Hipercolesterolemia/tratamento farmacológico , Hipercolesterolemia/terapia , Pravastatina/administração & dosagem , Pravastatina/farmacologia , Pravastatina/uso terapêutico , Argentina , Estudos Multicêntricos como Assunto , Fatores de RiscoRESUMO
PURPOSE--To evaluate the effects of pravastatin on lipoproteins, Lp (a), apo B and apo A-I and its tolerability in primary hypercholesterolemic patients in our outpatient lipid clinic. METHODS--Twenty-two primary hypercholesterolemic patients were evaluated. They had all been treated previously with other hypocholesterolemic drugs, including the statins, forming a specific and homogeneous group with hypercholesterolemia and definite coronary risk. After 7 weeks with American Heart Association phase I diet and placebo drug, pravastatin was administered during 12 weeks. All patients received an initial daily dose of 10 mg for six weeks. After this period, this dose was increased to 20 mg. The levels of cholesterol, triglycerides, high-density lipoprotein, lipoprotein (a) and apolipoproteins A-1 and B were determined. RESULTS--No changes occurred with diet and placebo, but pravastatin at a daily dose of 10 mg, reduced significantly cholesterol level (7.22 per cent) LDL-cholesterol (13.08 per cent) and increased HDL-cholesterol (7.8 per cent). The results were better with 20 mg, achieving a reduction of (28.21 per cent) in cholesterol, (36.88 per cent) in LDL-cholesterol, (17.06 per cent) in apo B level and an increase of (10.06 per cent) in HDL-cholesterol. The smaller effect observed with the more commonly used dosage (10 mg/day) was most probably due to the characteristics of the sample with already established hypercholesterolemia, being thus dependent of higher concentrations of medications, as observed in previous treatments in our outpatient clinic. Side affects with this drug were rare. No biochemical changes were observed that would interrupt the continuation of therapy. CONCLUSION--Pravastatin was well tolerated and promoted favorable changes in the total cholesterol, LDL, apo B and cholesterol/HDL and LDL/HDL ratios of primary hypercholesterolemic patients
Assuntos
Humanos , Masculino , Feminino , Adulto , Pessoa de Meia-Idade , Pravastatina/farmacologia , Hipercolesterolemia/tratamento farmacológico , Lipoproteínas , Pravastatina/administração & dosagem , HDL-Colesterol/efeitos dos fármacos , LDL-Colesterol/efeitos dos fármacos , Apolipoproteína A-I , Apolipoproteínas B , Lipoproteína(a)RESUMO
Estatinas säo drogas derivadas de microorganismos e que eficientemente interferem na síntese celular de colesterol por inibiçäo competitiva da enzima HMG-CoA-redutase. Näo obstante, as estatinas reduzem a colesterolemia por induzirem formaçäo de receptores que captam as LDL do plasma e por diminuirem a síntese de VLDL no fígado. Esta última explica o efeito parcial na queda da trigliceridemia. A eficiência das estatinas na diminuiçäo da colesterolemia é comparável à das resinas seqüestradoras de ácidos biliares, porém superios à dos fibrates e ácido nicotínico. Estatinas säo melhor toleradas do que estas últimas duas drogas, mas inferiores quanto à capacidade de diminuirem os triglicérides e de aumentarem o HDL-colesterol. Seletividade tissular varia entre as diversas estatinas, mas esta é uma questäo irrelevante tendo em vista a raridade dos efeitos colaterais. Conseqüentemente, estas drogas devem ser prescritas em razäo da potência farmacológica e do fator custo. Cinecoronarioangiografia seqüencial em pacientes com coronariopatia tratados com placebo em comparaçäo a estatinas isoladamente, indica que a doença arterial regride por métodos farmacológicos.
Assuntos
Humanos , Lovastatina/farmacologia , Pravastatina/farmacologia , Hipercolesterolemia/metabolismo , Lovastatina/análogos & derivados , Hidroximetilglutaril-CoA Redutases/efeitos dos fármacos , Hidroximetilglutaril-CoA Redutases/metabolismo , Lipoproteínas , Lipoproteínas/metabolismoRESUMO
A segurança da pravastatina, um inibidor seletivo hidrofílico da HMG-CoA redutase, foi avaliada em 1.142 pacientes adultos hipercolesterolêmicos em seis ensaios clínicos multicêntricos realizados nos Estados Unidos. Todos os ensaios foram aleatórios, duplo-cegos e controlados por placebo ao menos nas primeiras oito a 16 semanas, mantendo-se a seguir o tratamento a longo prazo com pravastatina em esquema duplo-cego ou aberto, com ou sem outras drogas redutoras de lipídios; o controle ativo primário foi a resina biliar de ligaçao a ácidos. Nao houve diferenças entre os grupos de pravastatina e placebo com relaçao às taxas globais de reaçoes adversas atribuíveis à droga. Somente erupçoes cutâneas (rash) ocorreram com maior freqúência estatística (p < 0,01) nos pacientes tratados com pravastina. Essas erupçoes geralmente eram leves e transitórias e somente 1,3 por cento dos casos relatados em pacientes tratados com pravastatina estavam possivelmente relacionados à terapia. Durante um período médio de tratamento de 18 meses, as razoes mais freqüentes para a interrupçao da administraçao de pravastatina foram queixas abdominais leves (1,4 por cento dos pacientes) e aumentos assintomáticos das transaminases hepáticas (1,0 por cento dos pacientes). Os valores médios de ALAT e ASAT aumentaram ligeiramente, atingindo um patamar estável após as primeiras oito semanas de terapia. Nenhuma ocorrência de enzimas hepáticas anormais entre os pacientes tratados com pravastina foi associada a doença clínica. Aumentos semelhantes das transaminases hepáticas também foram observados nos pacientes tratados com resina. Em geral, a pravastatina foi bem tolerada e aparentemente nao afetou os músculos esqueléticos, o sono ou o desenvolvimento de catarata.